Role of alternatively spliced tissue factor in pancreatic cancer growth and angiogenesis

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 2, 2008, Pages 161-169

  Signaevsky, Maxim ^a   Hobbs, Jennifer ^b   Doll, Jennifer ^c   Liu, Na ^a   Soff, Gerald A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alternatively spliced human tissue factor; Angiogenesis; Cancer progression; Metastasis; Tissue factor

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; PROCOAGULANT; THROMBOPLASTIN; VITAMIN K GROUP;

ANGIOGENESIS; ANTICOAGULATION; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL LINE; CYTOPLASM; EXON; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ALTERNATIVE SPLICING; ANIMALS; ANTICOAGULANTS; CELL LINE, TUMOR; HUMANS; MICE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; THROMBOPLASTIN; TRANSFECTION;

EID: 48749088059     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-2008-1079256     Document Type: Article

References (40)

1. Broze GJJ. The tissue factor pathway of coagulation. In: Loscalzo J, Schafer A, eds. Thrombosis and Hemorrhage. Philadelphia, PA: Lippincott Williams & Wilkins; 2003: 62-80
2. Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int J Hematol 2004;79:103-108
3. Mackman N. Alternatively spliced tissue factor - one cut too many? Thromb Haemost 2007;97:5-8
4. Eilertsen KE, Osterud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 2004;15:521-538
5. Donati MB, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol 2001;106:18-24
6. Falanga A. Thrombosis and malignancy: an underestimated problem. Haematologica 2003;88:607-610
7. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004;5:655-663
8. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005;6:401-410
9. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995;82:1101-1104
10. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9:458-462
11. Bogdanov VY, Kirk RI, Miller C, et al. Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost 2006;4:158-167
12. Ruf W, Schullek JR, Stone MJ, Edgington TS. Mutational mapping of functional residues in tissue factor: identification of factor VII recognition determinants in both structural modules of the predicted cytokine receptor homology domain. Biochemistry 1994;33:1565-1572
13. Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005;96:1233-1239
14. Censarek P, Bobbe A, Grandoch M, Schror K, Weber AA. Alternatively spliced human tissue factor (asHTF) is not procoagulant. Thromb Haemost 2007;97:11-14
15. Hobbs JE, Zakarija A, Cundiff DL, et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007;120(Suppl 2):S13-S21
16. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007;5(Suppl l):246-254
17. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003;124:58S-68S
18. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13:2870-2875
19. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007;5:520-527
20. Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998; 140:1241-1253
21. Versteeg HH, Spek CA, Slofstra SH, Diks SH, Richel DJ, Peppelenbosch MP. FVIIa:TF induces cell survival via G12/ G13-dependent Jak/STAT activation and BclXL production. Circ Res 2004;94:1032-1040
22. Ruf W. Tissue factor and PAR signaling in tumor progression. Thromb Res 2007;120(Suppl 2):S7-S12
23. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A 1995;92:8205-8209
24. Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of t+issue factor. Proc Natl Acad Sci U S A 1999;96:8663-8668
25. Palumbo JS, Degen JL. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res 2007;120(Suppl 2):S22-S28
26. Bobek V, Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004;58:213-219
27. Hembrough TA, Swartz GM, Papathanassiu A, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003;63:2997-3000
28. Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998;101:1372-1378
29. Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999;82:88-92
30. Versteeg HH, Schaffner F, Kerver M, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008;111:190-199
31. Palumbo JS, Talmage KE, Massari JV, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007;110:133-141
32. Smorenburg SM, Hettiarachchi RJ, Vink R, Buller HR. The effects of unfractionated heparin on survival in patients with malignancy - a systematic review. Thromb Haemost 1999;82: 1600-1604
33. Smorenburg SM, Vink R, Otten HM, Swaneveld F, Buller HR. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 2001;86:1586-1587
34. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153
35. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129
36. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-1948
37. Kakkar AK. Thrombosis and cancer. Hematol J 2004; 5(Suppl 3):S20-S23
38. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135
39. Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005;11:2531-2539
40. Haas SL, Jesnowski R, Steiner M, et al. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 2006;12: 4843-4849